NCT01776424
Rivaroxaban for the Prevention of Major Cardiovascular Events in Coronary or Peripheral Artery Disease
See it on ClinicalTrials.gov ↗27,395 people
22%
78%
6,020 womenmiddle line = equal numbers21,375 men
- Phase
- PHASE3
- Paid for by
- Bayer
- Finished
- 2021-06-15
- Health conditions
- Prevention & Control
- Who could join
- Anyone
- Ages
- 18 Years – no maximum
- Average age
- mean 68.2 Years
- Age 65+
- Not reported
- Weight (BMI)
- Not reported
- Pregnancy recorded
- Not reported
- Menopause recorded
- Not reported
- Results shown by sex
- Not split by sex
- Race
- White 62.2% · Hispanic / Latina 19.3% · Asian 15.6% · Other 2% · Black / African American 1%
Women left out
- No heart disease
Women with heart disease, heart rhythm problems or a past heart attack were turned away.
“Severe heart failure with known ejection fraction \<30% or New York Heart Association (NYHA) class III or IV symptoms”
Study titles and rules are shown in their original English.